Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Amyotrophic Lateral Sclerosis Treatment Market

Amyotrophic Lateral Sclerosis Treatment Market Share

Report ID: GMI11664
Published Date: Oct 2024
Report Format: PDF

Download Free Sample

Amyotrophic Lateral Sclerosis Treatment Market Share

The market is highly competitive, characterized by rapid innovation and technological advancements. Leading pharmaceutical companies hold a significant share of the market, driven by their extensive portfolios of diagnostic tests and advanced treatment options, including a range of medications and emerging therapeutic modalities. Strategic initiatives such as mergers, acquisitions, and collaborations further strengthen the market positions of key players, enabling them to expand their product offerings and access new markets.

Amyotrophic Lateral Sclerosis Treatment Market Companies

The company profile section includes both companies that have commercial drugs available in the market as well as those that are onto clinical phase development. Prominent players operating in the amyotrophic lateral sclerosis treatment industry include:

AB Science
Biogen Inc.
Biohaven Pharmaceutical (Pfizer, Inc.)
BrainStorm Therapeutics, Inc.
Corestemchemon Inc.
Eledon Pharmaceuticals, Inc.
F. Hoffmann-La Roche Ltd
Ionis Pharmaceuticals, Inc.
ITF Pharma GmbH
Mitsubishi Tanabe Pharma Corporation
Otsuka America Pharmaceutical, Inc.
Sun Pharmaceutical Industries Ltd.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The global market for amyotrophic lateral sclerosis treatments was valued at USD 713.3 million in 2023 and is projected to grow at a 5.5% CAGR from 2024 to 2032, driven by the rising incidence of ALS, increased awareness, advancements in therapeutic technologies, and the development of novel treatment options.

The market is segmented into medication, stem cell therapy, and other treatment types. In 2023, the medication segment dominated the market, accounting for USD 479.7 million.

The North American market for ALS treatments is expected to grow at a 5.2% CAGR, reaching USD 515.6 million by 2032. The U.S. represents a significant portion of this market, driven by the high prevalence of the disease and a robust healthcare infrastructure.

Prominent companies in the ALS treatment industry include AB Science, Biogen Inc., Biohaven Pharmaceutical (a subsidiary of Pfizer, Inc.), BrainStorm Therapeutics, Inc., Corestemchemon Inc., Eledon Pharmaceuticals, Inc., F. Hoffmann-La Roche Ltd, Ionis Pharmaceuticals, Inc., and ITF Pharma GmbH. These companies have either commercial drugs available or are in clinical development phases.